In this Genetic Engineering & Biotechnology News article by Richard A. Stein, Immuneering’s Head of Neuroscience J.L. Ross, Ph.D. discusses the company’s integration of biomarkers with bioinformatic, proteomic, and gene signature information…
In this article by Zach Winn, Immuneering co-founder and CEO Ben Zeskind discusses his journey from MIT undergraduate to biotech entrepreneur. He speaks to the company’s decade-plus of experience helping…
Breakthroughs in artificial intelligence (AI) hold enormous potential as it can automate complex tasks and go even beyond human performance. In their study, McKinney et al.1 showed the high potential…
Oncolytic viruses (OVs) are a new class of cancer therapeutics. This review was undertaken to provide insight into the current landscape of OV clinical trials. A PubMed search identified 119…
Huntington disease (HD), a devastating hereditary neurodegenerative disorder, is caused by an expansion of a CAG trinucleotide repeat that encodes a polyglutamine (polyQ) tract in the huntingtin (HTT) gene.
CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) — Immuneering Corporation today announced the company’s participation in Oppenheimer’s Private Life Sciences Company Call Series taking place virtually August 17-19, 2020. Immuneering…
The recent global pandemic has placed a high priority on identifying drugs to prevent or lessen clinical infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused by Coronavirus disease-2019…
CAMBRIDGE, Mass., June 25, 2020 (GLOBE NEWSWIRE) — Immuneering Corporation today announced a collaboration between its neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals (UK), a wholly owned subsidiary…
Although substantial concerns about the inflammatory effects of engineered nanomaterial (ENM) have been raised, experimentally assessing toxicity of various ENMs is challenging and time-consuming. Alternatively, quantitative structure–activity relationship (QSAR) models…
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune…
© 2020 Immuneering Corporation.
